Method for influenza virus purification
A process for the purification of influenza virus or derivative thereof requires providing a source of influenza virus or derivative thereof, optionally subjecting the source to a pre-purification step, followed by subjecting the source to at least one chromatographic step on chromatographic material selected from the group consisting of porous particles having mean pore sizes of at least 20 nm, perfusion particles, gel-in-a-shell particles, tentacle like particles, membrane adsorbers, and monoliths, and collecting fractions eluted from the chromatographic material that contain the influenza virus or derivative thereof, excluding sulfuric ester of cellulose or cross-linked polysaccharides.
1. A process for the purification of infective influenza virus selected from the group consisting of influenza virus wild type and influenza virus containing mutations, comprising the steps of:
providing a source containing the influenza virus in an infectious state;
subjecting the source to a pre-purification step selected from the group consisting of centrifugation, tangential flow filtration ultrafiltration, selective precipitation, expanded bed chromatography, batch chromatography utilizing magnetic beads and combinations thereof;
followed by more than one anion exchange chromatographic step on chromatographic anion exchange monoliths arranged in parallel and having positively charged functional groups on the monolith surface and selected from the group consisting of monoliths having ethylene diamine (EDA) groups, monoliths having quaternary amine (QA) groups, and monoliths having diethylaminoethyl (DEAE) groups, each chromatographic step utilizing, independently, a loading buffer having a pH of 7-8 and an elution buffer containing about 0.3M-1M NaCl, thereby,
obtaining a fraction with infective virus in a yield of at last about 40%; and
subjecting the obtained fraction to size exclusion chromatography;
with the proviso that sulfuric ester of cellulose and sulfuric ester of cross-linked polysaccharides are excluded.
2. The process of claim 1 , wherein the influenza virus in an infectious state contains at least one modification and/or deletion of the NS1 gene.
3. A process for the purification or manufacturing of infective influenza virus, comprising the steps of:
infecting cells with influenza virus;
propagating the infectious influenza virus in the cells;
harvesting the infectious influenza viruses; and
subjecting the infectious harvested influenza virus to the purification process according to claim 1 .
4. A process of the purification of infective influenza virus, comprising the steps of:
infecting cells with influenza virus;
propagating the infectious influenza virus in the cells;
harvesting the infectious influenza virus;
subjecting the concentrated infectious influenza virus to the purification process according to claim 1 , wherein the pre-purification step comprises concentrating the infectious harvested influenza virus by tangential flow filtration on a flat sheet or hollow fiber membrane with a 300 kDa cut off, and with the monoliths having positively charged functional groups comprising a poly(glycidyl methacrylate-co-ethylene dimethacrylate) matrix having quaternary amine (QA) functional groups;
sterile filtration of infectious influenza virus fractions eluted from the size exclusion chromatography.
5. An infectious influenza virus obtained according to the process of claim 1 .
6. A vaccine comprising influenza virus purified according to the process of claim 1 .
7. The vaccine of claim 6 further comprising an adjuvant, a pharmaceutically acceptable carrier, or both.
8. A vaccine comprising an influenza virus purified according to the process of claim 4 .
9. The process of claim 1 , wherein, after the at least one anion exchange chromatographic step, an ultrafiltration and/or sterile filtration is performed.
10. A vaccine comprising an influenza virus purified according to the process of claim 3 .